Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCproject_0031_T1_RNA

— · A

d051a3a1-67ab-561d-9bbd-6d1d1d801882

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.620
  • ANGIOGENESIS+0.560
  • HEDGEHOG_SIGNALING+0.520
  • MYOGENESIS+0.470
  • UV_RESPONSE_DN+0.470
  • COAGULATION+0.460
  • PANCREAS_BETA_CELLS+0.420
  • CHOLESTEROL_HOMEOSTASIS+0.410
  • APICAL_JUNCTION+0.390
  • HYPOXIA+0.370

Top 10 suppressed

  • E2F_TARGETS-0.610
  • MYC_TARGETS_V1-0.540
  • G2M_CHECKPOINT-0.530
  • MYC_TARGETS_V2-0.370
  • UNFOLDED_PROTEIN_RESPONSE-0.360
  • INTERFERON_ALPHA_RESPONSE-0.300
  • PI3K_AKT_MTOR_SIGNALING-0.300
  • DNA_REPAIR-0.290
  • MTORC1_SIGNALING-0.290
  • PROTEIN_SECRETION-0.280

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-BH-A0DV-01A-21R-A12P-07
breast-umap@18
—A0.932
220020085.TNBC
breast-umap@18
—F0.920
3SRR8518203
breast-umap@18
—A0.902
445b4921e-fce7-41f8-bb63-ed98343ceec8
colon-landscapes@1
——0.895
5TCGA-22-4605-01A-21R-2125-07
lung-landscapes@6
—cohortSQ10.892
6SRR25617877
breast-umap@18
—A0.891
7C3L-02552
lung-landscapes@6
—cohortSQ10.890
8TCGA-BH-A0AZ-01A-21R-A12P-07
breast-umap@18
—A0.890
9TCGA-56-7731-01A-11R-2125-07
lung-landscapes@6
—cohortSQ10.884
10TCGA-BH-A0BP-01A-11R-A115-07
breast-umap@18
—A0.883

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 35 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.620Inavolisib— uncovered
ANGIOGENESIS0.560Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.520Inavolisib— uncovered
MYOGENESIS0.470Inavolisib— uncovered
UV_RESPONSE_DN0.470Inavolisib— uncovered
COAGULATION0.460Binimetinib— uncovered
PANCREAS_BETA_CELLS0.420Cobimetinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.410Remibrutinib— uncovered
APICAL_JUNCTION0.390Inavolisib— uncovered
HYPOXIA0.370Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.350Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.330Inavolisib— uncovered
ADIPOGENESIS0.310Inavolisib— uncovered
IL2_STAT5_SIGNALING0.310Idelalisib— uncovered
KRAS_SIGNALING_UP0.310Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.310Inavolisib— uncovered
APICAL_SURFACE0.300Temsirolimus— uncovered
FATTY_ACID_METABOLISM0.290Inavolisib— uncovered
KRAS_SIGNALING_DN0.290Remibrutinib— uncovered
BILE_ACID_METABOLISM0.260Inavolisib— uncovered